Xenon Pharmaceuticals Inc... (XENE)
Xenon Pharmaceuticals Statistics
Share Statistics
Xenon Pharmaceuticals has 76.54M shares outstanding. The number of shares has increased by 1.42% in one year.
Shares Outstanding | 76.54M |
Shares Change (YoY) | 1.42% |
Shares Change (QoQ) | 0.4% |
Owned by Institutions (%) | 97.9% |
Shares Floating | 74.21M |
Failed to Deliver (FTD) Shares | 158 |
FTD / Avg. Volume | 0.03% |
Short Selling Information
The latest short interest is 2.89M, so 3.79% of the outstanding shares have been sold short.
Short Interest | 2.89M |
Short % of Shares Out | 3.79% |
Short % of Float | 3.94% |
Short Ratio (days to cover) | 7.75 |
Valuation Ratios
The PE ratio is -13.03 and the forward PE ratio is -11.04. Xenon Pharmaceuticals's PEG ratio is -1.27.
PE Ratio | -13.03 |
Forward PE | -11.04 |
PS Ratio | 0 |
Forward PS | 3.3 |
PB Ratio | 4.04 |
P/FCF Ratio | -16.83 |
PEG Ratio | -1.27 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Xenon Pharmaceuticals.
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 17.85, with a Debt / Equity ratio of 0.01.
Current Ratio | 17.85 |
Quick Ratio | 17.85 |
Debt / Equity | 0.01 |
Debt / EBITDA | -0.03 |
Debt / FCF | -0.05 |
Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity | n/a |
Return on Assets | n/a |
Return on Invested Capital | n/a |
Revenue Per Employee | $0 |
Profits Per Employee | $-741.55K |
Employee Count | 316 |
Asset Turnover | 0 |
Inventory Turnover | n/a |
Taxes
Income Tax | 4.09M |
Effective Tax Rate | -1.72% |
Stock Price Statistics
The stock price has increased by -23.85% in the last 52 weeks. The beta is 1.26, so Xenon Pharmaceuticals's price volatility has been higher than the market average.
Beta | 1.26 |
52-Week Price Change | -23.85% |
50-Day Moving Average | 37.3 |
200-Day Moving Average | 39.69 |
Relative Strength Index (RSI) | 30.89 |
Average Volume (20 Days) | 458.82K |
Income Statement
Revenue | n/a |
Gross Profit | 0 |
Operating Income | -279.3M |
Net Income | -234.33M |
EBITDA | -279.3M |
EBIT | n/a |
Earnings Per Share (EPS) | -3.01 |
Balance Sheet
The company has 142.71M in cash and 9.02M in debt, giving a net cash position of 133.7M.
Cash & Cash Equivalents | 142.71M |
Total Debt | 9.02M |
Net Cash | 133.7M |
Retained Earnings | -899.47M |
Total Assets | 798.14M |
Working Capital | 599.67M |
Cash Flow
In the last 12 months, operating cash flow was -181.39M and capital expenditures 0, giving a free cash flow of -181.39M.
Operating Cash Flow | -181.39M |
Capital Expenditures | 0 |
Free Cash Flow | -181.39M |
FCF Per Share | -2.33 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
XENE does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | n/a |
FCF Yield | n/a |
Analyst Forecast
The average price target for XENE is $57.5, which is 82.8% higher than the current price. The consensus rating is "Buy".
Price Target | $57.5 |
Price Target Difference | 82.8% |
Analyst Consensus | Buy |
Analyst Count | 8 |
Scores
Altman Z-Score | 33.81 |
Piotroski F-Score | 1 |